Anti-endotoxin properties of cationic host defence peptides and proteins

Journal of Endotoxin Research

Volumn 11, Issue 4, 2005, Pages 230-236

  Bowdish, Dawn M E ^a   Hancock, Robert E W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Endotoxin; Host defence peptides; Immunomodulator; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BMAP 28; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CECROPIN; CYTOKINE ANTIBODY; DROTRECOGIN; ENDOTOXIN; ENDOTOXIN ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; INDOLICIDIN; MELITTIN; PROTEGRIN; PROTEIN DERIVATIVE; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; SMAP 29; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; BACTEREMIA; CLINICAL TRIAL; DISEASE MODEL; DISEASE SEVERITY; DRUG MECHANISM; FEEDBACK SYSTEM; HOST CELL; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; REVIEW; SEPSIS; SEPTIC SHOCK;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ENDOTOXINS; FORECASTING; HUMANS; IMMUNITY, NATURAL; PEPTIDES; PROTEINS; RECEPTORS, CELL SURFACE; SEPSIS;

BACTERIA (MICROORGANISMS); FUNGI; MAMMALIA; VERMES;

EID: 25444458008     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805105X37394     Document Type: Review

References (77)

1. Natanson C, Esposito CJ, Banks SM. The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 1998; 26: 1927-1931.
2. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med 1998; 26: 2078-2086.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
4. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
5. Harris BH, Gelfand JA. The immune response to trauma. Semin Pediatr Surg 1995; 4: 77-82.
6. Frank ED, Kaufman D, Korman H, Schweinburg F, Frank HA, Fine J. Effect of antibiotics on hemodynamics of hypovolemic septic shock. Am J Physiol 1955; 182: 166-176.
7. Periti P, Mazzei T. New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock. Int J Antimicrob Agents 1999; 12: 97-105.
8. Polderman KH, Girbes AR. Drug intervention trials in sepsis: divergent results. Lancet 2004; 363: 1721-1723.
9. Sevransky JE, Parent C, Cui X et al. Granulocyte colony-stimulating factor has differing effects comparing intravascular versus extravascular models of sepsis. J Trauma 2004; 57: 618-625.
10. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003; 7: 108-114.
11. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 2004; 4: 1147-1171.
12. Diamond G, Russell JP, Bevins CL. Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells. Proc Natl Acad Sci USA 1996; 93: 5156-5160.
13. Nell MJ, Sandra Tjabringa G, Vonk MJ, Hiemstra PS, Grote JJ. Bacterial products increase expression of the human cathelicidin hCAP-18/LL-37 in cultured human sinus epithelial cells. FEMS Immunol Med Microbiol 2004; 42: 225-231.
14. De Y, Chen Q, Schmidt AP et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000; 192: 1069-1074.
15. 7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol 2004; 172: 4987-4994.
16. Scott MG, Hancock REW. Cationic antimicrobial peptides and their multifunctional role in the immune system. Crit Rev Immunol 2000; 20: 407-431.
17. Davidson DJ, Currie AJ, Reid GS et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004; 172: 1146-1156.
18. van Wetering S, Mannesse-Lazeroms SP, van Sterkenburg MA, Hiemstra PS. Neutrophil defensins stimulate the release of cytokines by airway epithelial cells: modulation by dexamethasone. Inflamm Res 2002; 51: 8-15.
19. Lau YE, Rozek A, Scott MG, Goosney DL, Davidson DJ, Hancock REW. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect Immun 2005; 73: 583-591.
20. Yang D, Chen Q, Hoover DM et al. Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol 2003; 74: 448-455.
21. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004; 75: 39-48.
22. Powers JP, Hancock REW. The relationship between peptide structure and antibacterial activity. Peptides 2003; 24: 1681-1691.
23. Larrick JW, Hirata M, Zheng H et al. A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol 1994; 152: 231-240.
24. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995; 63: 1291-1297.
25. VanderMeer TJ, Menconi MJ, Zhuang J et al. Protective effects of a novel 32-amino acid C-terminal fragment of CAP18 in endotoxemic pigs. Surgery 1995; 117: 656-662.
26. Kirikae T, Hirata M, Yamasu H et al. Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. Infect Immun 1998; 66: 1861-1868.
27. Scott MG, Vreugdenhil AC, Buurman WA, Hancock REW, Gold MR. Cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol 2000; 164: 549-553.
28. [see 26]
29. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002; 169: 3883-3891.
30. Ohgami K, Ilieva IB, Shiratori K et al. Effect of human cationic antimicrobial protein 18 peptide on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 2003; 44: 4412-4418.
31. Giacometti A, Cirioni O, Ghiselli R et al. The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis. Crit Care Med 2004; 32: 2485-2490.
32. Rogy MA, Oldenburg HS, Calvano SE et al. The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. J Clin Immunol 1994; 14: 120-133.
33. Scott MG, Gold MR, Hancock REW. Interaction of cationic peptides with lipoteichoic acid and Gram-positive bacteria. Infect Immun 1999; 67: 6445-6453.
34. Britigan BE, Lewis TS, Waldschmidt M, McCormick ML, Krieg AM. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J Immunol 2001; 167: 2921-2928.
35. Weiss J, Franson RC, Beckerdite S, Schmeidler K, Elsbach P. Partial characterization and purification of a rabbit granulocyte factor that increases permeability of Escherichia coli. J Clin Invest 1975; 55: 33-42.
36. 2 from rabbit polymorphonuclear leukocytes. Observations on their relationship. J Biol Chem 1979; 254: 11000-11009.
37. Weiss J, Muello K, Victor M, Elsbach E. The role of lipopolysaccharides in the action of the bactericidal/permeability-increasing neutrophil protein on the bacterial envelope. J Immunol 1984; 132: 3109-3115.
38. Tobias PS, Mathison JC, Ulevitch RJ. A family of lipopolysaccharide binding proteins involved in responses to Gram-negative sepsis. J Biol Chem 1988; 263: 13479-13481.
39. Marra MN, Wilde CG, Griffith JE, Snable JL, Scott RW. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 1990; 144: 662-666.
40. Beamer LJ, Carroll SF, Eisenberg D. The three-dimensional structure of human bactericidal/permeability-increasing protein: implications for understanding protein-lipopolysaccharide interactions. Biochem Pharmacol 1999; 57: 225-229.
41. 2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal /permeability-increasing protein. J Biol Chem 1987; 262: 14891-14894.
42. Gazzano-Santoro H, Parent JB, Grinna L et al. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun 1992; 60: 4754-4761.
43. Jiang Z, Hong Z, Guo W et al. A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo. Int Immunopharmacol 2004; 4: 527-537.
44. Ciornei CD, Egesten A, Engstrom M, Tornebrandt K, Bodelsson M. Bactericidal/permeability-increasing protein inhibits endotoxin-induced vascular nitric oxide synthesis. Acta Anaesthesiol Scand 2002; 46: 1111-1118.
45. Kluger MS. Vascular endothelial cell adhesion and signaling during leukocyte recruitment. Adv Dermatol 2004; 20: 163-201.
46. Kakkar AK, Lefer DJ. Leukocyte and endothelial adhesion molecule studies in knockout mice. Curr Opin Pharmacol 2004; 4: 154-158.
47. Huang K, Fishwild DM, Wu HM, Dedrick RL. Lipopolysaccharide-induced E-selectin expression requires continuous presence of US and is inhibited by bactericidal/permeability-increasing protein. Inflammation 1995; 19: 389-104.
48. Marra MN, Wilde CG, Collins MS, Snable JL, Thornton MB, Scott RW. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992; 148: 532-537.
49. Meszaros K, Parent JB, Gazzano-Santoro H et al. A recombinant amino terminal fragment of bactericidal/permeability-increasing protein inhibits the induction of leukocyte responses by LPS. J Leukoc Biol 1993; 54: 558-563.
50. Corradin SB, Heumann D, Gallay P, Smith J, Mauel J, Glauser MP. Bactericidal/permeability-increasing protein inhibits induction of macrophage nitric oxide production by lipopolysaccharide. J Infect Dis 1994; 169: 105-111.
51. 2-terminal fragment cause killing of serum-resistant Gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 1992; 90: 1122-1130.
52. Jiang J, Zhu P, Wang Z et al. Protective effect of bactericidal/permeability-increasing protein in mice with E. coli sepsis. Chin J Traumatol 1998; 1: 21-24.
53. Jiang J, Xie G, Liu D et al. Effect of bactericidal/permeability-increasing protein on sepsis induced by intra-abdominal infection in rats. Chin J Traumatol 1999; 2: 84-86.
54. Kohn FR, Ammons WS, Horwitz A et al. Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia. J Infect Dis 1993; 168: 1307-1310.
55. Vandermeer TJ, Menconi MJ, O'Sullivan BP et al. Bactericidal/permeability-increasing protein ameliorates acute lung injury in porcine endotoxemia. J Appl Physiol 1994; 76: 2006-2014.
56. 23) on cerebrospinal fluid inflammation induced by endotoxin. J Infect Dis 1995; 171: 948-953.
57. Rogy MA, Moldawer LL, Oldenburg HS et al. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI. Ann Surg 1994; 220: 77-85.
58. Giroir BP, Quint PA, Barton P et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 1997; 350: 1439-1443.
59. 21 Meningococcal Sepsis Study Group. Lancet 2000; 356: 961-967.
60. Sorensen OE, Follin P, Johnsen AH et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001; 97: 3951-3959.
61. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998; 42: 2206-2214.
62. Nagaoka I, Hirota S, Niyonsaba F et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J Immunol 2001; 167: 3329-3338.
63. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock REW. Impact of LL-37 on anti-infective immunity. J Leukoc Biol 2004; 77: 451-459.
64. Giacometti A, Cirioni O, Ghiselli R et al. Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. Am J Respir Crit Care Med 2004; 169: 187-194.
65. Nagpal S, Kaur KJ, Jain D, Salunke DM. Plasticity in structure and interactions is critical for the action of indolicidin, an antibacterial peptide of innate immune origin. Protein Sci 2002; 11: 2158-2167.
66. Bowdish DM, Davidson, DJ, Scott M, Hancock, REW. Immunomodulatory activities of small host defence peptides. Antimicrob Agents Chemother 2005; 49: 1727-1732.
67. Ciornei CD, Egesten A, Bodelsson M. Effects of human cathelicidin antimicrobial peptide LL-37 on lipopolysaccharide-induced nitric oxide release from rat aorta in vitro. Acta Anaesthesiol Scand 2003; 47: 213-220.
68. Fukumoto K, Nagaoka I, Yamataka A et al. Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. Pediatr Surg Int 2005; 21: 20-24.
69. Gough M, Hancock REW, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996; 64: 4922-4927.
70. Sawyer JG, Martin NL, Hancock REW. Interaction of macrophage cationic proteins with the outer membrane of Pseudomonas aeruginosa. Infect Immun 1988; 56: 693-698.
71. Hancock REW, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43: 1317-1323.
72. Ferguson AD, Welte W, Hofmann E et al. A conserved structural motif for lipopolysaccharide recognition by procaryotic and eucaryotic proteins. Structure Fold Des 2000; 8: 585-592
73. Andra J, Koch MH, Bartels R, Brandenburg K. Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin. Antimicrob Agents Chemother 2004; 48: 1593-1599.
74. Scott MG, Rosenberger CM, Gold MR, Finlay BB, Hancock REW. An alpha-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression. J Immunol 2000; 165: 3358-3365.
75. Giacometti A, Cirioni O, Ghiselli R et al. Potential therapeutic role of cationic peptides in three experimental models of septic shock. Antimicrob Agents Chemother 2002; 46: 2132-2136.
76. Giacometti A, Cirioni O, Ghiselli R et al. Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock. Peptides 2003; 24: 1747-1752.
77. Thomas JA, Tsen MF, White DJ, Horton JW. TLR4 inactivation and rBPI(21) block burn-induced myocardial contractile dysfunction. Am J Physiol 2002; 283: H1645-H1655.